Editorial: P2X7 as Common Therapeutic Target in Brain Diseases

• Tobias Engel,
• Tobias Engel,
• Annette Nicke,
• Jan M. Deussing,
• Beata Sperlagh,
• Miguel Diaz-Hernandez,
• Miguel Diaz-Hernandez

Affiliations

Tobias Engel

Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland

Tobias Engel

FutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland

Annette Nicke

Faculty of Medicine, Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universität München, Munich, Germany

Jan M. Deussing

Molecular Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany

Beata Sperlagh

Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, Budapest, Hungary

Miguel Diaz-Hernandez

Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Madrid, Spain

Miguel Diaz-Hernandez

Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain